Correction to: LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis

Correction: Cancer Cell Int (2021) 21:284

https://doi.org/10.1186/s12935-021-01993-x

In the original article, the author would like to make the below changes in bold.

Western blotting.

RIPA buffer (Sigma, USA) was used to isolate protein, and there proteins were then separated by 10% SDS-PAGE, transferred to PVDF membranes (Millipore, MA, USA),

Results.

The levels of lncRNA WDFY3AS2 in OC cells with different levels of cisplatin sensitivity.

SDC4 expression in A2780-DDP cells was inhibited by the miR-139-5p mimic, while SDC4 expression was increased in the miR-139-5p inhibitor group (Fig. 5C, D, P < 0.001). The correlation analysis demonstrated that SDC4 expression was negatively correlated with miR-139-5p (r=-0.6851, P < 0.01 Fig. 5E). These findings indicated that SDC4 was targeted by miR-139-5p negatively. Furthermore, co-transfection of the miR-139-5p inhibitor could rescue the SDC4 expression reduced by si-WDFY3-AS2 in A2780-DDP cells (Fig. 5F,G, P < 0.001).

The weights and volumes of tumors in animals that had been administered the miR-139-5p inhibitor or SDC4 were notably increased relative to the si-WDFY3-AS2 mice (all P < 0.001, Fig. 7D-F).

We found that overexpression of the WDFY3-AS2 increased cell viability, migration, and invasion, inhibited apoptosis, as well as OC CSC traits induction, as shown by induced tumor sphere formation, CD44-,CD166-positive cell numbers, and the expression levels of CSC markers both in vitro and in vivo.